{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Colon&page=59", "query": { "condition": "Cancer Colon", "page": 59 }, "page_size": 10 }, "pagination": { "page": 59, "page_size": 10, "total_count": 3056, "total_pages": 306, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Colon&page=60&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Colon&page=58&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T11:27:48.514Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03258398", "title": "A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Microsatellite Stable Relapsed or Refractory Colorectal Cancer" ], "interventions": [ { "name": "eFT508", "type": "DRUG" }, { "name": "Avelumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Effector Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2017-09-18", "completion_date": "2019-05-13", "has_results": false, "last_update_posted_date": "2019-07-18", "last_synced_at": "2026-10-31T11:27:48.514Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Denver, Colorado • Sarasota, Florida + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03258398" }, { "nct_id": "NCT01586416", "title": "Intervention to Increase Chemotherapy Tolerance in Elderly Cancer Patients", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Colonic Neoplasms" ], "interventions": [ { "name": "Behavioral Intervention", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 15, "start_date": "2012-12", "completion_date": "2020-12", "has_results": false, "last_update_posted_date": "2020-09-02", "last_synced_at": "2026-10-31T11:27:48.514Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01586416" }, { "nct_id": "NCT00873275", "title": "Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "FOLFOX regimen", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "ursodiol", "type": "DRUG" }, { "name": "RNA analysis", "type": "GENETIC" }, { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "western blotting", "type": "GENETIC" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "positron emission tomography (PET)", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "GENETIC", "OTHER", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2009-03-11", "completion_date": "2025-02-26", "has_results": false, "last_update_posted_date": "2025-06-22", "last_synced_at": "2026-10-31T11:27:48.514Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00873275" }, { "nct_id": "NCT04306900", "title": "TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "TTX-030, budigalimab and mFOLFOX6", "type": "COMBINATION_PRODUCT" }, { "name": "TTX-030, budigalimab and docetaxel", "type": "COMBINATION_PRODUCT" }, { "name": "TTX-030 and mFOLFOX6", "type": "COMBINATION_PRODUCT" }, { "name": "TTX-030 and budigalimab", "type": "COMBINATION_PRODUCT" }, { "name": "TTX-030, budigalimab, nab-paclitaxel and gemcitabine", "type": "COMBINATION_PRODUCT" }, { "name": "TTX-030 and pembrolizumab", "type": "COMBINATION_PRODUCT" }, { "name": "TTX-030, nab-paclitaxel and gemcitabine", "type": "COMBINATION_PRODUCT" }, { "name": "Budigalimab and mFOLFOX6", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Trishula Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "110 Years", "sex": "ALL", "summary": "18 Years to 110 Years" }, "enrollment_count": 185, "start_date": "2020-03-30", "completion_date": "2024-03-27", "has_results": true, "last_update_posted_date": "2025-07-29", "last_synced_at": "2026-10-31T11:27:48.514Z", "location_count": 26, "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 21 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04306900" }, { "nct_id": "NCT00478634", "title": "A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Colorectal Carcinoma", "Colorectal Tumors", "Neoplasms, Colorectal" ], "interventions": [ { "name": "RAD001, Cetuximab, Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 19, "start_date": "2007-05", "completion_date": "2009-09", "has_results": false, "last_update_posted_date": "2012-11-02", "last_synced_at": "2026-10-31T11:27:48.514Z", "location_count": 16, "location_summary": "Fayetteville, Arkansas • Bakersfield, California • La Jolla, California + 13 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00478634" }, { "nct_id": "NCT00817934", "title": "Safe, Effective, and More Tolerable 16 Tablets Colon Prep", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Colon Cancer" ], "interventions": [ { "name": "AB PREP", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Long Neck Medical Enterprises", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "12 Years to 75 Years" }, "enrollment_count": 400, "start_date": "2009-01", "completion_date": "2010-01", "has_results": false, "last_update_posted_date": "2009-01-07", "last_synced_at": "2026-10-31T11:27:48.514Z", "location_count": 1, "location_summary": "Millsboro, Delaware", "locations": [ { "city": "Millsboro", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT00817934" }, { "nct_id": "NCT05366881", "title": "cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Brain Cancer", "Breast Cancer", "Bladder Cancer", "Cervical Cancer", "Colorectal Cancer", "Endometrial Cancer", "Esophageal Cancer", "Stomach Cancer", "Head and Neck Cancer", "Hepatobiliary Cancer", "Leukemia", "Lung Cancer", "Lymphoma", "Multiple Myeloma", "Ovarian Cancer", "Pancreatic Cancer", "Prostate Cancer", "Renal Cancer", "Sarcoma", "Thyroid Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Adela, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 7000, "start_date": "2022-05-03", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-01-20", "last_synced_at": "2026-10-31T11:27:48.514Z", "location_count": 17, "location_summary": "Duarte, California • Miami, Florida • Gainesville, Georgia + 14 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Gainesville", "state": "Georgia" }, { "city": "New Albany", "state": "Indiana" }, { "city": "Corbin", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT05366881" }, { "nct_id": "NCT00511862", "title": "TheraSphere for the Treatment of Liver Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer", "Carcinoma, Neuroendocrine", "Neoplasm Metastasis" ], "interventions": [ { "name": "Yttrium 90 glass microspheres", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Boston Scientific Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 151, "start_date": "2007-01", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2021-05-13", "last_synced_at": "2026-10-31T11:27:48.514Z", "location_count": 5, "location_summary": "Chicago, Illinois • Baltimore, Maryland • Rochester, Minnesota + 2 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Albany", "state": "New York" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00511862" }, { "nct_id": "NCT04761783", "title": "BESPOKE Study of ctDNA Guided Immunotherapy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Colorectal Cancer", "Melanoma", "Non-small Cell Lung Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Natera, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 290, "start_date": "2021-05-28", "completion_date": "2024-03-30", "has_results": false, "last_update_posted_date": "2024-08-15", "last_synced_at": "2026-10-31T11:27:48.514Z", "location_count": 1, "location_summary": "San Carlos, California", "locations": [ { "city": "San Carlos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04761783" }, { "nct_id": "NCT06529523", "title": "Tislelizumab in People With Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Tislelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2024-07-26", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-10-31T11:27:48.514Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06529523" } ] }